EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety

Clinical trial NCT07523581 · RECRUITING

Trial details

NCT number: NCT07523581
Sponsor: Eloxx Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Alport Syndrome, X-Linked Alport Syndrome, Autosomal Recessive

Start date: 2026-06-30
Primary completion: 2027-06-30
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.